The Epidermolysis Bullosa Medical Research Foundation (EBMRF) was established in 1991 to fund research for Epidermolysis Bullosa, a group of genetic disorders causing severe skin blistering. EBMRF promotes innovative medical research aimed at finding cures and effective treatments for EB patients, while ensuring all operational costs are covered by volunteers to maximize funding available for research.
Not Reported
94-3130081
$3.8 million
This organization contributes to the following United Nations Sustainable Development Goals. See the SDG page for more information.
The FDA's recent approvals mark significant milestones in the treatment of epidermolysis bullosa.
Annual fundraising event that has raised millions for EB research.
A special jewelry piece designed to support the foundation, with proceeds benefiting EB research.
FDA Approval of Vyjuvek
The FDA approved Vyjuvek, a topical gene therapy drug for wound treatment in dystrophic EB.
FDA Approval of Filsuvez
The FDA approved Filsuvez, a topical gel for wound treatment in EB patients aged 6 months and older.
Total Funds Raised
Raised nearly $10 million for EB research since inception.
2020-05-18
An online auction featuring celebrity meet & greets to aid families in need of EB.
2019-01-16
Special music event honoring Chris Cornell featuring performances by major artists.
2018-11-12
Annual fundraiser featuring food and wine tastings to support EB research.
2024-05-06
An annual fundraising concert featuring performances from various artists.
Learn MoreMed Research
Medical Research Funding - Multiple OrgMed Research
Medical Research Funding - Multiple OrgMed Research
Medical Research Funding - Multiple OrgMed Research
Medical Research Funding - Multiple OrgMed Research
Medical Research Funding - Multiple Org